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OBJECTIVE: Thyroidectomy is associated with a high incidence of postoperative nausea and
vomiting (PONV), ranging from 60% to 84%. We conducted this study to compare the antiemetic
effects and safety of granisetron 20 µg/kg and ramosetron 4 µg/kg in patients undergoing elective
thyroidectomy under standard anaesthetic technique.
METHODS: One hundred and thirteen patients were randomized to receive placebo (n = 41),
granisetron 20 µg/kg (n = 36) or ramosetron 4 µg/kg (n = 36) intravenously over 2–5 minutes
immediately before the induction of anaesthesia. The incidence of PONV, nausea severity score (NSS),
adverse events and the need for rescue antiemetics were assessed during the first 1 hour (0–1 h) and
following 23 hours (1–24 h) after anaesthesia.
RESULTS: During the first hour after anaesthesia, the incidence of PONV was 36.6% for placebo,
11.1% for granisetron (p = 0.012 vs placebo) and 25.0% for ramosetron. During 1 hour to 23 hours
after anaesthesia, the incidence of PONV was 51.2% for placebo, 30.6% for granisetron and 41.7%
for ramosetron. There were no significant differences between the three groups. Overall (0–24 h), the
corresponding incidence of PONV were 61.0%, 30.6% and 50.0%, respectively, showing a signifi-
cantly lower value in the granisetron group than in the placebo group (p = 0.008). The incidence of
vomiting and rescue antiemetic requirement during the first 24 hours after anaesthesia was significantly
lower with the granisetron group than with placebo (p = 0.021 and 0.030, respectively). The most
common adverse events in the three groups were headache and dizziness.
CONCLUSION: Only granisetron 20 µg/kg was superior to placebo for the prevention of PONV
after thyroidectomy. (Asian J Surg 2002;25(4):309–14)
INTRODUCTION
Postoperative nausea and vomiting (PONV) are com-
mon and distressing symptoms.1 In previous studies,2 the
average early (within 6 hours after surgery) and late
(within 48 hours) incidences of PONV were reported as
40% and 60%, respectively. Thyroidectomy is associated
with relatively high incidences of PONV, ranging from
60% to 84%,3,4 and antiemetics such as metoclopramide
or alizapride do not prevent PONV effectively.3
Ramosetron (Nausea, Yamanouchi, Tokyo, Japan) as
well as granisetron (Kytril, Smith Kline Beecham, London,
UK) are selective 5-hydroxytryptamine type 3 (5-HT3)
receptor antagonists. Ramosetron is more potent and
longer acting than granisetron against cisplatin-induced
emesis.5 Both drugs also have been used for the treatment
of PONV.6–12 They lack the sedative, dysphoric and
extrapyramidal symptoms associated with other traditional
antiemetics, such as droperidol and metoclopramide.13
The lack of associated side-effects makes the use of 5-HT3
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pyridostigmine 0.03 mg/kg i.v. at the end of surgery. The
patient was extubated when fully awake. Placement of a
nasal or oral gastric tube during surgery was not permitted.
Anaesthesia duration was defined as the period from
induction until the discontinuation of nitrous oxide and
was recorded for all patients. Postoperative analgesia
consisted of 30 mg tarasyn, as required.
After completion of surgery, all episodes of PONV
(nausea, retching or vomiting) were recorded during the
first 24 hours after anaesthesia, covering two time periods
(0–1 h in the postanaesthesia care unit and 1–24 h in the
general ward). Specially trained nurses performed the
questioning, and they were blinded to study the groups. In
the post-anaesthesia care unit and general ward, recordings
were performed every 30 minutes and 6 hours, respectively.
Nausea was defined as a subjective, unpleasant sensation
associated with awareness of the urge to vomit. Retching
was defined as laboured, spastic, rhythmic contraction of
the respiratory muscles without the expulsion of gastric
contents, and vomiting was defined as the forceful
expulsion of gastric contents from the mouth.14 Retching
or vomiting was recorded as either present or absent. If the
patient had nausea, the severity of the episode was
recorded during each assessment period using the
following scale: 1 = mild nausea, 2 = moderate nausea
and 3 = severe nausea. The highest score during each
assessment period was recorded. A rescue antiemetic
(e.g., metoclopramide 10 mg i.v. or i.m.) was allowed at
the request of the patient or upon the advice of a doctor.
Adverse events were recorded during the 24-hour
postoperative period. Patients were questioned specifically
about any possible side-effects of the study medication
and then asked to volunteer any other complaints.
Statistical analyses of the data between groups were
performed by one-way analysis of variance (ANOVA)
with Bonferroni’s correction for multiple comparisons,
the chi-square test or Fisher’s exact probability test, as
appropriate. P < 0.05 was considered significant. All
values were expressed as mean ± SD or number (%).
RESULTS
A total of 113 patients were recruited. The numbers of
patients receiving placebo, granisetron and ramosetron
were 41, 36 and 36, respectively. There were no signifi-
cant differences in patient characteristics (Table 1).
The incidence of PONV during the first hour after
anaesthesia was 36.6%, 11.1% and 25.0% in patients
receptor antagonists attractive. Nonetheless, they are
expensive compared with traditional antiemetics.6
Furthermore, the incidence of drug-related side effects,
such as headache, increases in a dose-dependant man-
ner.2  Therefore, it is necessary to discover the lowest
dose required for preventing PONV. In previous studies,
7–9,11 granisetron 40 µg/kg and ramosetron 0.3 mg were
re-ported as minimum effective doses for preventing
PONV. However, there are a few reports using lower
dosages of the two drugs.
This prospective, randomized, double-blind study
was designed to compare the efficacy of ramosetron
(4 µg/kg) with granisetron (20 µg/kg) in preventing PONV
in patients undergoing thyroidectomy under standard
anaesthetic technique.
PATIENTS AND METHODS
After approval by the local Ethics Committee and
obtaining informed consent from patients, we studied
113 ASA physical status I or II patients, aged between
18 and 65 years, undergoing general anaesthesia for
elective thyroidectomy. Patients who were more
than 50% over ideal body weight, those who had
gastrointestinal diseases and had taken antiemetics within
24 hours prior to surgery were excluded from the study.
Patients were premedicated with midazolam 0.05mg/kg
and glycopyrrolate 0.004 mg/kg.
A medical history (including previous motion sickness,
prior PONV) was recorded along with demographic
information such as age, height and weight.
Patients were randomly allocated to receive placebo
(0.9% NaCl), granisetron 20 µg/kg or ramosetron 4 µg/kg
i.v. over 2–5 minutes immediately before the induction of
anaesthesia. All antiemetics were diluted with normal
saline (0.9% NaCl) to a total volume of 10 ml. Anaesthesia
was induced with thiopentone 5 mg/kg i.v. and vecuronium
0.1 mg/kg or succinylcholine 1–1.5 mg/kg i.v. was used to
facilitate tracheal intubation. After intubation, anaesthesia
was maintained with 1.5%–2.5% (inspired concentration)
enflurane and 50% nitrous oxide in 50% oxygen.
Ventilation was mechanically controlled and was adjusted
to maintain an end-tidal concentration of carbon dioxide
of between 3.5 kPa and 4.5 kPa throughout surgery with
an anaesthetic/respiratory analyzer (Dräger, Lübeck,
Germany). Muscle relaxation was achieved with
vecuronium or pancuronium and antagonized by a
combination of glycopyrrolate 0.002 mg/kg i.v. and
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who had received placebo, granisetron 20 µg/kg and
ramosetron 4 µg/kg, respectively. The incidence of PONV
was significantly lower in the granisetron group than in
the placebo group (p = 0.012). The corresponding
incidences during 1–24 hours after anaesthesia were
51.2%, 30.6% and 41.7%, respectively. There were no
significant differences between the three groups (p >
0.05). Overall, the corresponding incidences of PONV
during the 0–24-hour period after anaesthesia was
61.0%, 30.6% and 50.0%, respectively, with a
significantly lower value in the granisetron group than in
the placebo group (p = 0.008) (Table 2).
The incidence of nausea during 0–1 hour after anaes-
thesia was 29.3%, 11.1% and  22.2% in patients who had
received placebo, granisetron 20 µg/kg and ramosetron
4 µg/kg, respectively. There was a significant difference
between the granisetron and the placebo groups
(p = 0.045) (Table 2).
The incidence of vomiting during 1–24 hours after
anaesthesia and the entire 24 hours was significantly
lower (p = 0.036 and 0.021) in the granisetron group
(8.3% and 8.3%) compared with placebo (26.8% and
29.3%) (Table 2).
Patients in the granisetron group required signifi-
cantly less rescue antiemetics than those in the placebo
group during 1–24 hours after anaesthesia and the
entire 24 hours (Table 2). Nausea severity scores (NSSs)
were not significantly different between the three groups
(p > 0.05) (Table 2).
The most common untoward adverse events were
mild headache and dizziness. No differences in the
incidence of adverse events were observed among the
groups (p > 0.05) (Table 3).
DISCUSSION
We found that PONV was very common in thyroidec-
tomized patients and low-dose granisetron 20 µg/kg i.v.
was effective for the prevention of PONV during the first
24 hours after anaesthesia, without significant adverse
events. In this study, the incidence of PONV was 36.6%
(0–1 h), 51.2% (1–24 h) and 61.0% (overall, 0–24 h) in the
placebo group. And, the administration of granisetron
20 µg/kg i.v. immediately before induction anaesthesia
significantly reduced the incidence of PONV from 36.6%
to 11.1% (0–1 h) and 61.0% to 30.6% (overall, 0–24 h).
The etiology of PONV after surgery is multifactorial
and includes age, sex, weight, history of motion sickness
and/or previous PONV, surgical procedure as well as
anaesthetic technique.14–21 In this study, the three groups
were comparable for all factors that might have contributed
to PONV and, thus, it may be reasonably suggested that
the difference in the incidence of PONV among the
groups was attributed to the antiemetic administered.
During thyroidectomy, age range, patient’s sex (mostly
young or middle-aged women) and intense stimulation
of vagal afferents during surgical handling of the neck are
considered to increase the incidence of PONV.3,4
Dejonckheere and colleagues3 reported that the inci-
dence of PONV after thyroidectomy was 60%–84%.
Recently, Sonner et al reported that, in women patients
undergoing thyroid or parathyroid surgery, the incidence
Table 1. Demographic and anaesthesia data
Placebo Granisetron Ramosetron
(n = 41) 20 µg/kg (n = 36) 4 µg/kg (n = 36)
Sex, M/F 3/38 2/34 4/32
Age, yr   42.22 ± 11.34 37.70 ± 9.96 38.61 ± 9.50
Height, cm 157.12 ± 16.63 160.9 ± 7.48 159.28 ± 16.31
Weight, kg 59.59 ± 8.14 60.31 ± 7.82 58.25 ± 7.32
Duration of operation, min 162.44 ± 63.07 148.89 ± 70.79 153.33 ± 63.73
Duration of anaesthesia, min 177.32 ± 61.85 168.47 ± 67.59 173.75 ± 67.42
History of motion sickness, n (%) 11(26.8) 6 (16.7) 11 (30.6)
History of PONV, n (%) 4 (9.8) 1 (2.8) 0 (0)
Values are mean ± SD or number (%). n = patient numbers. PONV = postoperative nausea and vomiting. No significant
differences between groups.
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of PONV was 64% with isoflurane and 44% with
propofol.22 In our study, during the first 24 hours postop-
erative period the incidence of PONV was reported as
61.0% when using enflurane and this value is comparable
with the previous studies.3,4,22
Ramosetron, granisetron and odansetron are selective
5-hydroxytryptamine type 3 (5-HT3) receptor antagonists.
Granisetron is known to be more potent, and has longer-
acting activity against cisplatin-induced emesis than
ondansetron.23 Its mechanism of action is both central as
well as peripheral (gastrointestinal tract).24–27 It blocks
5-HT3 receptors in the mucosal vagal afferents, thereby
inhibiting the afferent arm of the vomiting reflex.27 Fujii
and colleagues7–9 demonstrated that 40 µg/kg granisetron
reduces the incidence of PONV after breast surgery,
middle-ear surgery and thyroidectomy. They also sug-
gested that 40 µg/kg granisetron appears to be the mini-
mum effective dose for preventing PONV in women
Table 2. Incidence of postoperative nausea and vomiting (PONV) during the first 24 hours after anaesthesia, rescue
antiemetic medication and severity of nausea
Placebo Granisetron Ramosetron
(n = 41) 20 µg/kg 4 µg/kg P1 P2 P3
(n = 36) (n = 36)
0–1 hour after anaesthesia
    PONV 15 (36.6) 4 (11.1) 9 (25.0) 0.012 0.273 0.139
    Nausea 12 (29.3) 4 (11.1) 8 (22.2) 0.045 0.482 0.206
    Retching or vomiting 3 (7.3) 0 (0) 1 (2.8) 0.098 0.370 0.314
    Rescue antiemetics 3 (7.3) 0 (0) 1 (2.8) 0.098 0.370 0.314
    Nausea severity score 1.33 ± 0.65 1.50 ± 1.00 2.00 ± 1.07 1.000 0.317 1.000
1–24 hours after anaesthesia
    PONV 21 (51.2) 11 (30.6) 15 (41.7) 0.066 0.402 0.326
    Nausea 10 (24.4) 8 (22.2) 10 (27.8) 0.823 0.735 0.586
    Retching or vomiting 11 (26.8) 8 (8.3) 4 (12.5) 0.036 0.163 0.453
    Rescue antiemetics 12 (29.3) 4 (11.1) 6 (16.7) 0.045 0.192 0.496
    Nausea severity score 2.22 ± 0.83 1.63 ± 0.74 1.60 ± 0.84 0.430 0.325 1.000
Overall
    PONV 25 (61.0) 11 (30.6) 18 (50.0) 0.008 0.333 0.093
    Nausea 13 (31.7) 8 (22.2) 12 (33.3) 0.351 0.879 0.293
    Retching or vomiting 12 (29.3) 3 (8.3) 6 (16.7) 0.021 0.192 0.285
    Rescue antiemetics 13 (31.7) 4 (11.1) 7 (19.4) 0.030 0.221 0.326
Values are number (%) or mean ± SD. P1 = placebo vs granisetron; P2 = placebo vs ramosetron; P3 = granisetron vs ramosetron.
Table 3. Incidence of adverse events
Placebo Granisetron 20 µg/kg Ramosetron 4 µg/kg
(n = 41) (n = 36) (n = 36)
Any adverse events 13 (31.7) 11 (30.6) 15 (41.7)
Headache 9 (22.0) 9 (25.0) 13 (36.1)
Dizziness 2 (4.9) 2 (5.6) 5 (13.9)
Others (constipation, muscle pain) 3 (7.3) 5 (13.9) 2 (5.6)
Values are number (%). No significant differences between groups.
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undergoing middle-ear surgery.8 In our study, granisetron
20 µg/kg i.v. was found to reduce the incidence of PONV
compared to placebo. This is not in  accordance with the
results of previous studies,7–9 which demonstrated that
granisetron 20 µg/kg i.v. was not effective for the
prevention of PONV.
Ramosetron has more potent and longer acting
properties than granisetron against cisplatin-induced
emesis.5 The precise mechanism of action of ramosetron
remains unclear, but it is thought to behave via the same
mechanism as granisetron.28 In previous studies,
ramosetron 0.3 mg was reported as the minimum effective
dose for the prevention of PONV and ramosetron 0.3 mg
as well as granisetron 3 mg effectively prevented PONV
after middle-ear surgery.11,12 In our study, the average
ramosetron and granisetron dosages used were 0.23 mg
(mean weight of 58.2 kg at 4 µg/kg) and 1.2 mg (mean
weight of 61.0 kg at 20 µg/kg), respectively. The dosage
of ramosetron was similar to that used in previous studies,
but in our study, it had no effect in the prevention of
PONV. In contrast, the dosage of granisetron was much
lower than that in previous studies, but showed superior-
ity over placebo in the prevention of PONV after
thyroidectomy. However, it only prevented PONV in
69.4% of patients in the first 24 hours postoperatively,
and 30% of patients still suffered from PONV. These
results suggest that more effective antiemetic therapy has
yet to be determined and this may include the use of
a higher ramosetron or granisetron dose and using
a combination of antiemetics that have different
mechanisms of action. However, when increasing the
5-HT3 receptor antagonist dosage, we should be wary that
the adverse events of the drug will increase simultaneously.
Tramer and colleagues reviewed the data for ondansetron
and reported that headache was the most common drug-
related adverse event and was dose dependent.2 In our
study, the most common untoward adverse events were
headache and dizziness and these were relatively mild.
No differences in the incidences of adverse events were
observed among the groups (Table 3).
CONCLUSION
Our study of the efficacy and safety of antiemetic
prophylaxis with i.v. granisetron 20 µg/kg and ramosetron
4 µg/kg revealed that, granisetron 20 µg/kg was an
effective antiemetic for the prevention of PONV after
thyroidectomy without significant adverse events.
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